-Network: (00 - Document - Document and Company Information)

-Document And Entity Information [Abstract] {ID1}

Entity Registrant Name {ID2}

Entity Central Index Key {ID3}

Document Type {ID4}

Document Period End Date {ID5}

Amendment Flag {ID6}

Amendment Description {ID7}

Current Fiscal Year End Date {ID8}

Entity Well-known Seasoned Issuer {ID9}

Entity Voluntary Filers {ID10}

Entity Current Reporting Status {ID11}

Entity Filer Category {ID12}

Entity Public Float {ID13}

Entity Common Stock, Shares Outstanding {ID14}

-Network: (01 - Statement - Consolidated Statements of Operations)

-Statements Of Operations [Abstract] {ID15}

-Statement [Table] {ID16}

-Statement [Line Items] {ID17}

-Revenue: {ID18}

Net product sales {ID19}

Collaborative agreements and other revenue {ID20}

Royalty revenue {ID21}

Total revenue {ID22}

-Expenses: {ID23}

Cost of goods sold (excluding amortization of acquired intangible assets) {ID24}

Research and development {ID25}

Selling, general and administrative {ID26}

Amortization of acquired intangible assets {ID27}

Acquired in-process research and development {ID28}

Total expenses {ID29}

Operating income (loss) {ID30}

-Other income and expense: {ID31}

Interest and investment income, net {ID32}

Equity in (income) losses of affiliated companies {ID33}

Interest expense {ID34}

Other income, net {ID35}

Income (loss) before income taxes {ID36}

Income tax provision {ID37}

Net income (loss) {ID38}

-Net income (loss) per common share: {ID39}

Basic {ID40}

Diluted {ID41}

-Weighted average shares (in thousands): {ID42}

Basic {ID43}

Diluted {ID44}

-Network: (02 - Statement - Consolidated Balance Sheets)

-Balance Sheets [Abstract] {ID45}

-Statement [Table] {ID46}

-Statement [Line Items] {ID47}

-Assets {ID48}

-Current assets: {ID49}

Cash and cash equivalents {ID50}

Marketable securities available for sale {ID51}

Accounts receivable, net of allowances of $9,678 and $9,391 at June 30, 2009 and December 31, 2008, respectively {ID52}

Inventory {ID53}

Deferred income taxes {ID54}

Other current assets {ID55}

Total current assets {ID56}

Property, plant and equipment, net {ID57}

Investment in affiliated companies {ID58}

Intangible assets, net {ID59}

Goodwill {ID60}

Other assets {ID61}

Total assets {ID62}

-Liabilities and Stockholders' Equity {ID63}

-Current liabilities: {ID64}

Accounts payable {ID65}

Accrued expenses {ID66}

Income taxes payable {ID67}

Current portion of deferred revenue {ID68}

Other current liabilities {ID69}

Total current liabilities {ID70}

Deferred revenue, net of current portion {ID71}

Non-current income taxes payable {ID72}

Other non-current liabilities {ID73}

Total liabilities {ID74}

Commitments and Contingencies {ID75}

-Stockholders' Equity: {ID76}

Preferred stock, $.01 par value per share, 5,000,000 shares authorized; none outstanding at June 30, 2009 and December 31, 2008, respectively {ID77}

Common stock, $.01 par value per share, 575,000,000 shares authorized; issued 464,719,591 and 463,274,296 shares at June 30, 2009 and December 31, 2008, respectively {ID78}

Common stock in treasury, at cost; 6,198,012 and 4,144,667 shares at June 30, 2009 and December 31, 2008, respectively {ID79}

Additional paid-in capital {ID80}

Accumulated deficit {ID81}

Accumulated other comprehensive loss {ID82}

Total stockholders' equity {ID83}

Total liabilities and stockholders' equity {ID84}

-Network: (021 - Statement - Consolidated Balance Sheets (Parenthetical))

-Balance Sheets (Parenthetical) [Abstract] {ID85}

-Statement [Table] {ID86}

-Statement [Line Items] {ID87}

Allowances for accounts receivable {ID88}

Preferred stock, par value {ID89}

Preferred stock, shares authorized {ID90}

Preferred stock, shares outstanding {ID91}

Common stock, par value {ID92}

Common stock, shares authorized {ID93}

Common stock, shares issued {ID94}

Treasury shares, at cost {ID95}

-Network: (03 - Statement - Consolidated Statements of Cash Flows)

-Statements Of Cash Flows [Abstract] {ID96}

-Statement [Table] {ID97}

-Statement [Line Items] {ID98}

-Cash flows from operating activities: {ID99}

Net income (loss) {ID100}

-Adjustments to reconcile net income (loss) to net cash provided by operating activities: {ID101}

Depreciation of long-term assets {ID102}

Amortization of intangible assets {ID103}

Allocation of pre-paid royalties {ID104}

Provision for accounts receivable allowances {ID105}

Deferred income taxes {ID106}

Acquired in-process research and development {ID107}

Share-based compensation expense {ID108}

Equity in (income) losses of affiliated companies {ID109}

Share-based employee benefit plan expense {ID110}

Unrealized change in value of foreign currency forward contracts {ID111}

Realized gain on marketable securities available for sale {ID112}

Other, net {ID113}

-Change in current assets and liabilities, excluding the effect of acquisition: {ID114}

Accounts receivable {ID115}

Inventory {ID116}

Other operating assets {ID117}

Accounts payable and other operating liabilities {ID118}

Income tax payable {ID119}

Deferred revenue {ID120}

Net cash provided by operating activities {ID121}

-Cash flows from investing activities: {ID122}

Proceeds from sales of marketable securities available for sale {ID123}

Purchases of marketable securities available for sale {ID124}

Payments for acquisition of business, net of cash acquired {ID125}

Capital expenditures {ID126}

Investment in affiliated companies {ID127}

Purchases of investment securities {ID128}

Other {ID129}

Net cash used in investing activities {ID130}

-Cash flows from financing activities: {ID131}

Payment for treasury shares {ID132}

Net proceeds from exercise of common stock options and warrants {ID133}

Excess tax benefit from share-based compensation arrangements {ID134}

Net cash provided by (used in) financing activities {ID135}

Effect of currency rate changes on cash and cash equivalents {ID136}

Net increase (decrease) in cash and cash equivalents {ID137}

Cash and cash equivalents at beginning of period {ID138}

Cash and cash equivalents at end of period {ID139}

-Supplemental schedule of non-cash investing and financing activity: {ID140}

Change in net unrealized (gain) loss on marketable securities available for sale {ID141}

Matured shares tendered in connection with stock option exercises {ID142}

Conversion of convertible notes {ID143}

-Supplemental disclosure of cash flow information: {ID144}

Interest paid {ID145}

Income taxes paid {ID146}

-Network: (04 - Statement - Consolidated Statements of Stockholders Equity)

-Statements Of Stockholders Equity [Abstract] {ID147}

-Statement [Table] {ID148}

-Statement [Line Items] {ID149}

Beginning Balance {ID150}

-Other comprehensive income: {ID151}

Increase in unrealized gain on available for sale securities, net of tax of $5,211, $29,631 and $6,013 for 2008, 2007 and 2006 respectively {ID152}

Reversal of unrealized gains on Pharmion investment, net of tax of $38,904 {ID153}

Reclassification adjustment for losses included in net income (loss), net of tax of $736, $3,860 and $4,062 for 2008, 2007 and 2006 respectively {ID154}

Unrealized losses on cash flow hedges {ID155}

Pension liability adjustment {ID156}

Net asset transfer of common control foreign subsidiaries {ID157}

Currency translation adjustments {ID158}

Comprehensive income (loss) {ID159}

Treasury stock -mature shares tendered related to option exercise {ID160}

Issuance of common stock related to the 2:1 February 17, 2006 stock split {ID161}

Costs related to 2006 secondary stock offering {ID162}

Acquisition of Pharmion Corp. {ID163}

Conversion of long-term convertible notes {ID164}

Issuance of common stock related to the secondary stock offering {ID165}

Exercise of stock options and warrants {ID166}

Issuance of common stock for employee benefit plans {ID167}

Issuance of restricted stock {ID168}

Expense related to stock-based compensation {ID169}

Expense related to stock-based compensation and restricted stock granted to employees {ID170}

Income tax benefit upon exercise of stock options {ID171}

Ending Balance {ID172}

-Statement, Equity Components [Axis] {ID173}

-Equity Component [Domain] {ID174}

-Parent [Member] {ID175}

Common Stock {ID176}

Preferred Stock [Member] {ID177}

Capital Units [Member] {ID178}

Common Stock Including Additional Paid in Capital [Member] {ID179}

Preferred Stock Including Additional Paid in Capital [Member] {ID180}

-Additional Paid-in Capital {ID181}

Other Additional Capital [Member] {ID182}

Deferred Compensation, Share-based Payments [Member] {ID183}

Treasury Stock {ID184}

-Retained Earnings (Deficit) {ID185}

Retained Earnings, Appropriated [Member] {ID186}

Retained Earnings, Unappropriated [Member] {ID187}

Undistributed Income from Other than Gain or Loss on Sale of Properties [Member] {ID188}

Undistributed Net Realized Gain or Loss on Sale of Properties [Member] {ID189}

Accumulated Distributions in Excess of Net Income [Member] {ID190}

-Accumulated Other Comprehensive Income (Loss) {ID191}

Accumulated Net Unrealized Investment Gain (Loss) [Member] {ID192}

Accumulated Net Gain (Loss) from Designated or Qualifying Cash Flow Hedges [Member] {ID193}

Accumulated Translation Adjustment [Member] {ID194}

Accumulated Defined Benefit Plans Adjustment [Member] {ID195}

Noncontrolling Interest [Member] {ID196}

Comprehensive Income [Member] {ID197}

-Network: (041 - Statement - Consolidated Statements of Stockholders Equity (Parenthetical))

-Statement Of Stockholders Equity (Parenthetical) [Abstract] {ID198}

-Statement [Table] {ID199}

-Statement [Line Items] {ID200}

Tax effect on increase in unrealized gain on available for sale securities {ID201}

Tax effect on reversal of unrealized gains on Pharmion investment {ID202}

Tax effect on reclassification adjustment for losses included in net income (loss) {ID203}

-Statement, Equity Components [Axis] {ID204}

-Equity Component [Domain] {ID205}

-Parent [Member] {ID206}

Common Stock {ID207}

Preferred Stock [Member] {ID208}

Capital Units [Member] {ID209}

Common Stock Including Additional Paid in Capital [Member] {ID210}

Preferred Stock Including Additional Paid in Capital [Member] {ID211}

-Additional Paid-in Capital {ID212}

Other Additional Capital [Member] {ID213}

Deferred Compensation, Share-based Payments [Member] {ID214}

Treasury Stock {ID215}

-Retained Earnings (Deficit) {ID216}

Retained Earnings, Appropriated [Member] {ID217}

Retained Earnings, Unappropriated [Member] {ID218}

Undistributed Income from Other than Gain or Loss on Sale of Properties [Member] {ID219}

Undistributed Net Realized Gain or Loss on Sale of Properties [Member] {ID220}

Accumulated Distributions in Excess of Net Income [Member] {ID221}

-Accumulated Other Comprehensive Income (Loss) {ID222}

Accumulated Net Unrealized Investment Gain (Loss) [Member] {ID223}

Accumulated Net Gain (Loss) from Designated or Qualifying Cash Flow Hedges [Member] {ID224}

Accumulated Translation Adjustment [Member] {ID225}

Accumulated Defined Benefit Plans Adjustment [Member] {ID226}

Noncontrolling Interest [Member] {ID227}

Comprehensive Income [Member] {ID228}

-Network: (0601 - Disclosure - Nature of Business and Basis of Presentation)

-Nature Of Business And Basis Of Presentation [Abstract] {ID229}

Nature Of Business And Basis Of Presentation {ID230}

-Network: (0602 - Disclosure - Summary of Significant Accounting Policies)

-Summary Of Significant Accounting Policies [Abstract] {ID231}

Summary of Significant Accounting Policies {ID232}

-Network: (0603 - Disclosure - Acquisition of Pharmion Corporation)

-Acquisition Of Business [Abstract] {ID233}

Acquisition of Pharmion Corporation {ID234}

-Network: (0604 - Disclosure - Restructuring)

-Restructuring [Abstract] {ID235}

Restructuring {ID236}

-Network: (0605 - Disclosure - Earnings Per Share (EPS))

-Earnings Per Share Disclosure [Abstract] {ID237}

Earnings Per Share (EPS) {ID238}

-Network: (0606 - Disclosure - Comprehensive Income (Loss))

-Comprehensive Income (Loss) [Abstract] {ID239}

Comprehensive Income (Loss) {ID240}

-Network: (0607 - Disclosure - Financial Instruments and Fair Value Measurement)

-Financial Instruments And Fair Value Measurement [Abstract] {ID241}

Financial Instruments and Fair Value Measurement {ID242}

-Network: (0608 - Disclosure - Derivative Instruments And Hedging Activities)

-Derivative Instruments And Hedging Activities [Abstract] {ID243}

Derivative Instruments and Hedging Activities {ID244}

-Network: (0609 - Disclosure - Cash, Cash Equivalents and Marketable Securities Available for Sale)

-Cash, Cash Equivalents And Marketable Securities Available-For-Sale [Abstract] {ID245}

Cash, Cash Equivalents and Marketable Securities Available-for-Sale {ID246}

-Network: (0610 - Disclosure - Inventory)

-Inventory [Abstract] {ID247}

Inventory {ID248}

-Network: (0611 - Disclosure - Investment in Affiliated Companies)

-Investment In Affiliated Companies [Abstract] {ID249}

Investment in Affiliated Companies {ID250}

-Network: (0612 - Disclosure - Intangible Assets and Goodwill)

-Intangible Assets and Goodwill [Abstract] {ID251}

Intangible Assets and Goodwill {ID252}

-Network: (0613 - Disclosure - Share Based Compensation)

-Share Based Compensation Disclosure [Abstract] {ID253}

Share-Based Compensation {ID254}

-Network: (0614 - Disclosure - Income Taxes)

-Income Taxes [Abstract] {ID255}

Income Taxes {ID256}

-Network: (0615 - Disclosure - Collaboration Agreements)

-Collaboration Agreements [Abstract] {ID257}

Collaboration Agreements {ID258}

-Network: (0616 - Disclosure - Commitments and Contingencies)

-Commitments and Contingencies [Abstract] {ID259}

Commitments and Contingencies {ID260}

-Network: (0617 - Disclosure - Subsequent Event)

-Subsequent Event [Abstract] {ID261}

Subsequent Event {ID262}

CELGENE CORPORATION XBRL Taxonomy Presentation Networks